ASCO 2015 Highlights

CMS’s Coverage Decision on Provenge: Implications for Payers
By Dalia Buffery, MA, ABD
Health Policy, Policies & Guidelines
April 2011, Vol 2, No 2
On March 30, 2011, the Centers for Medicare & Medicaid Services (CMS) announced its highly anticipated proposed national coverage decision concerning the prostate cancer immunotherapy sipuleucel-T (Provenge; Dendreon).
Read Article

Page 317 of 330

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.